Published in Cancer Weekly, March 7th, 2006
Hycamtin is the first drug to be approved in Europe that is specifically indicated for the treatment of relapsed SCLC. Data from the Hycamtin clinical trials show that treatment with Hycamtin is associated with prolonged survival and quality of life compared to best supportive care in patients battling the disease.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.